Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Over the last 12 months, insiders at Mirum Pharmaceuticals, Inc. have bought $4.62M and sold $2.71M worth of Mirum Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Mirum Pharmaceuticals, Inc. have bought $56.09M and sold $5.18M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Heron Patrick J () — $33.78M. BJERKHOLT ERIC (Chief Financial Officer) — $1.19M.
The last purchase of 2,000 shares for transaction amount of $49,600 was made by BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) on 2024‑03‑27.
2024-06-24 | Sale | Vig Pamela | CHIEF SCIENTIFIC OFFICER | 30,559 0.0633% | $34.00 | $1.04M | -4.91% | |
2024-06-05 | Sale | Ramasastry Saira | director | 5,000 0.0104% | $25.68 | $128,400 | +2.66% | |
2024-03-27 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 2,000 0.0042% | $24.80 | $49,600 | +0.80% | ||
2024-03-25 | Sale | Radovich Peter | PRESIDENT AND COO | 4,303 0.0091% | $25.80 | $111,017 | -3.59% | |
2024-03-18 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 2,000 0.0043% | $25.80 | $51,600 | -2.57% | ||
2024-02-02 | Sale | Longpre Lara | CHIEF DEVELOPMENT OFFICER | 847 0.0018% | $26.19 | $22,184 | -2.06% | |
2024-02-02 | Sale | Peetz Christopher | CHIEF EXECUTIVE OFFICER | 6,013 0.0127% | $26.19 | $157,491 | -2.06% | |
2024-02-02 | Sale | Radovich Peter | PRESIDENT AND COO | 1,790 0.0038% | $26.19 | $46,883 | -2.06% | |
2024-02-02 | Sale | Vig Pamela | CHIEF SCIENTIFIC OFFICER | 1,214 0.0026% | $26.19 | $31,797 | -2.06% | |
2024-02-02 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 735 0.0015% | $26.19 | $19,251 | -2.06% | |
2024-01-08 | Sale | Peetz Christopher | PRESIDENT AND CEO | 5,209 0.011% | $28.03 | $146,033 | -7.93% | |
2024-01-08 | Sale | Longpre Lara | CHIEF DEVELOPMENT OFFICER | 1,019 0.0022% | $28.04 | $28,568 | -7.93% | |
2024-01-08 | Sale | Radovich Peter | CHIEF OPERATING OFFICER | 1,408 0.003% | $28.03 | $39,473 | -7.93% | |
2024-01-08 | Sale | Vig Pamela | HEAD OF RESEARCH & DEVELOPMENT | 1,408 0.003% | $28.03 | $39,472 | -7.93% | |
2024-01-08 | Sale | Howe Jolanda | SVP, GLOBAL CONTROLLER | 528 0.0011% | $28.04 | $14,803 | -7.93% | |
2023-12-05 | Sale | Howe Jolanda | SVP, Global Controller | 2,500 0.0053% | $32.40 | $81,000 | -18.94% | |
2023-09-14 | Sale | GREY MICHAEL G | director | 14,216 0.0367% | $32.00 | $454,912 | -13.60% | |
2023-09-13 | Heron Patrick J | director | 2,625 0.0068% | $31.02 | $81,425 | -6.64% | ||
2023-09-12 | Heron Patrick J | director | 3,750 0.0096% | $30.60 | $114,764 | -9.92% | ||
2023-09-11 | Heron Patrick J | director | 4,687 0.0122% | $30.30 | $142,027 | -8.02% |
Heron Patrick J | director | 159053 0.3412% | $32.86 | 5 | 0 | +5.09% |
Longpre Lara | CHIEF DEVELOPMENT OFFICER | 104407 0.224% | $32.86 | 1 | 5 | |
Peetz Christopher | CHIEF EXECUTIVE OFFICER | 104112 0.2233% | $32.86 | 4 | 5 | +41.16% |
Radovich Peter | PRESIDENT AND COO | 29013 0.0744% | $32.86 | 0 | 6 | |
Vig Pamela | CHIEF SCIENTIFIC OFFICER | 27406 0.0615% | $32.86 | 1 | 6 | +53.04% |
BJERKHOLT ERIC | Chief Financial Officer | 14000 0.0215% | $32.86 | 3 | 0 | |
Howe Jolanda | SVP, GLOBAL CONTROLLER | 1759 0.0038% | $32.86 | 0 | 5 | |
GREY MICHAEL G | director | 0 0% | $32.86 | 0 | 3 | |
Ramasastry Saira | director | 0 0% | $32.86 | 0 | 1 | |
Chang Carmen | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
MOTT DAVID M | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
Behbahani Ali | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
BARRIS PETER J | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
BASKETT FOREST | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
MAKOWER JOSHUA | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
SANDELL SCOTT D | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
Sonsini Peter W. | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
Makhzoumi Mohamad | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
Walker Paul Edward | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
Florence Anthony A. Jr. | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
New Enterprise Associates 16, L.P. | 10 percent owner | 4186243 8.9806% | $32.86 | 1 | 0 | +5.09% |
Frazier Life Sciences IX, L.P. | 10 percent owner | 3566912 7.652% | $32.86 | 1 | 0 | +5.09% |
Novo Holdings A/S | 10 percent owner | 2445147 5.2455% | $32.86 | 1 | 0 | +5.09% |
O'Donnell Niall | director | 1621118 3.4777% | $32.86 | 1 | 3 | +5.09% |
Deerfield Healthcare Innovations Fund, L.P. | 1540190 3.3041% | $32.86 | 0 | 1 | ||
Tucker Edwin Jonathan | Chief Medical Officer | 45768 0.0982% | $32.86 | 2 | 1 | +71.87% |
Clements Ian | Chief Financial Officer | 18561 0.0398% | $32.86 | 4 | 1 | +42.68% |
Brege Laura | director | 10000 0.0215% | $32.86 | 1 | 0 | +63.65% |
Fischer Laurent | director | 6750 0.0145% | $32.86 | 5 | 0 | +66.98% |
Flynn James E | 10 percent owner | 0 0% | $32.86 | 1 | 4 | +5.09% |
Frazier Life Sciences Management L P | $163.16M | 13.78 | 6.5M | 0% | +$0 | 8.38 | |
Bvf Inc Il | $109.78M | 9.27 | 4.37M | 0% | +$0 | 0.81 | |
Eventide Asset Management | $82.91M | 7 | 3.3M | +23.91% | +$16M | 1.31 | |
State Street | $70.9M | 5.99 | 2.82M | +62.7% | +$27.32M | <0.01 | |
Janus Henderson | $69.47M | 5.87 | 2.77M | +34.16% | +$17.69M | 0.04 | |
BlackRock | $61.6M | 5.2 | 2.45M | -0.39% | -$238,062.24 | <0.01 | |
Cadian Capital Management LP | $57.59M | 4.86 | 2.29M | +18.48% | +$8.98M | 2.05 | |
The Vanguard Group | $55.56M | 4.69 | 2.21M | -10.68% | -$6.65M | <0.01 | |
ROCK SPRINGS CAPITAL MANAGEMENT, LP | $46.64M | 3.94 | 1.86M | +0.28% | +$128,112.00 | 1.19 | |
T. Rowe Price | $40.13M | 3.39 | 1.6M | +37.16% | +$10.87M | 0.01 | |
Novo Holdings A/S | $37.68M | 3.18 | 1.5M | 0% | +$0 | 2.63 | |
Citadel Advisors LLC | $34.98M | 2.95 | 1.39M | -3.49% | -$1.26M | 0.02 | |
Tang Capital Management, LLC | $29.82M | 2.52 | 1.19M | +4.4% | +$1.26M | 0.12 | |
Avidity Partners Management Lp | $28.71M | 2.42 | 1.14M | 0% | +$0 | 1.04 | |
Franklin Templeton Investments | $23.65M | 2 | 941,374 | +3.1% | +$711,046.72 | 0.01 | |
Goldman Sachs | $17.59M | 1.49 | 700,116 | +53.43% | +$6.12M | <0.01 | |
Geode Capital Management | $17.52M | 1.48 | 697,139 | +2.34% | +$400,960.62 | <0.01 | |
William Blair Investment Management | $15.76M | 1.33 | 627,272 | +0.88% | +$138,009.28 | 0.04 | |
Polar Capital | $15.7M | 1.33 | 625,000 | 0% | +$0 | 0.09 | |
AXA | $14.92M | 1.26 | 593,786 | +0.01% | +$1,833.76 | 0.05 | |
Millennium Management LLC | $13.56M | 1.15 | 539,666 | +140.52% | +$7.92M | 0.01 | |
Prosight Management Lp | $11.68M | 0.99 | 465,000 | +58.54% | +$4.31M | 3.25 | |
Boone Capital Management Llc | $11.35M | 0.96 | 451,898 | -7.8% | -$960,613.94 | 2.3 | |
Citigroup | $9.32M | 0.79 | 371,051 | +335.35% | +$7.18M | 0.01 | |
Morgan Stanley | $8.91M | 0.75 | 354,588 | +44.91% | +$2.76M | <0.01 | |
Bank of America | $7.85M | 0.66 | 312,613 | +107.27% | +$4.06M | <0.01 | |
Nuveen | $7.82M | 0.66 | 311,185 | -33.84% | -$4M | <0.01 | |
Northern Trust | $7.06M | 0.6 | 281,079 | -2.42% | -$174,734.71 | <0.01 | |
Barclays | $6.9M | 0.58 | 274,866 | +175.08% | +$4.39M | <0.01 | |
Charles Schwab | $6.82M | 0.58 | 271,654 | +1.86% | +$124,921.75 | <0.01 | |
Rafferty Asset Management Llc | $6.69M | 0.57 | 266,262 | +104.27% | +$3.41M | 0.02 | |
ClearBridge Investments | $6.62M | 0.56 | 263,584 | -0.19% | -$12,886.56 | 0.01 | |
Penn Capital Management Co Inc | $6.18M | 0.52 | 245,696 | -0.01% | -$804.90 | 0.24 | |
Elequin Securities Llc | $6.18M | 0.52 | 245,696 | +264,089.25% | +$6.18M | 0.24 | |
Ardsley Advisory Partners | $6.15M | 0.52 | 245,000 | +8.89% | +$502,400.00 | 0.89 | |
Deutsche Bank | $6.13M | 0.52 | 244,151 | +42.34% | +$1.82M | <0.01 | |
Qube Research & Technologies | $6.07M | 0.51 | 241,498 | +93.75% | +$2.94M | 0.01 | |
Woodline Partners LP | $5.86M | 0.5 | 233,267 | -7.89% | -$502,299.52 | 0.06 | |
Ensign Peak Advisors Inc | $5.59M | 0.47 | 222,614 | 0% | +$0 | 0.01 | |
Rice Hall James & Associates, LLC | $5.4M | 0.46 | 214,887 | +401.6% | +$4.32M | 0.33 | |
Altium Capital Management Lp | $5.22M | 0.44 | 208,000 | New | +$5.22M | 2.43 | |
Two Sigma Advisers LP | $4.95M | 0.42 | 197,000 | -41.42% | -$3.5M | 0.01 | |
New York State Common Retirement Fund | $4.94M | 0.42 | 196,679 | -11.75% | -$657,823.59 | 0.01 | |
Baker Bros Advisors LP | $4.78M | 0.4 | 190,476 | 0% | +$0 | 0.06 | |
Silvercrest Asset Management Group Inc | $4.09M | 0.35 | 162,817 | +64.55% | +$1.6M | 0.03 | |
Adage Capital Partners Gp L L C | $4.02M | 0.34 | 160,000 | -72.17% | -$10.42M | 0.01 | |
Affinity Asset Advisors | $4.02M | 0.34 | 160,000 | +220% | +$2.76M | 0.71 | |
UBS | $3.94M | 0.33 | 156,911 | +32.37% | +$963,854.57 | <0.01 | |
Two Sigma | $3.9M | 0.33 | 155,353 | -20.79% | -$1.02M | 0.01 | |
Nicholas Investment Partners, L.P. | $3.79M | 0.32 | 151,002 | -62.14% | -$6.23M | 0.43 |